EUVIMEDEUVIMED entdecken
Fallbericht

Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature

Nihaal Reddy iD, Katarina Vasiljevic, Rebecca Shatsky iD

JCO Precision Oncology · 2026-08 · 10 (8)

DOI: 10.1200/po-25-00628 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCO Precision Oncology, 2026-08. Verfasst von Nihaal Reddy und 2 weiteren Autor:innen. Beteiligte Einrichtung: UC San Diego Health, San Diego, CA. Die Arbeit nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • UC San Diego Health, San Diego, CA.
  • Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Irvine, CA.

ORCID-Profile: Nihaal Reddy, Rebecca Shatsky

Zitieren

APA

Reddy, N., Vasiljevic, K., & Shatsky, R. (2026). Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature. JCO Precision Oncology, 10(8). https://doi.org/10.1200/po-25-00628

Vancouver

Reddy N, Vasiljevic K, Shatsky R. Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature. JCO Precision Oncology. 2026;10(8). doi:10.1200/po-25-00628

BibTeX
@article{Reddy2026,
  author = {Reddy, Nihaal and Vasiljevic, Katarina and Shatsky, Rebecca},
  title = {Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {8},
  doi = {10.1200/po-25-00628}
}
Kostenlos starten →